How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

3,334 results for

Myocardial Infarction Stabilization

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

3141. Temozolomide Plus Carboplatin in Treating Patients With Recurrent Glioblastoma Multiforme

PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At least 12 weeks Hematopoietic: Granulocyte count greater than 1,500/mm3 Platelet count greater than 100,000/mm3 Hemoglobin at least 10.0 g/dL Hepatic: Bilirubin no greater than 1.5 times normal SGOT no greater than 3 times upper limit of normal Renal: Creatinine clearance greater than 50 mL/min Cardiovascular: No myocardial infarction within the past 6 months No congestive heart failure requiring therapy Other (...) a pharmacokinetic or pharmacodynamic-mediated drug interaction in patients treated with this regimen. V. Determine the objective response rate and stabilization rate in patients treated with this regimen at the MTD. VI. Determine the acute and long-term toxic effects of this regimen at the MTD in these patients. VII. Determine the time to tumor progression and survival of patients treated with this regimen. OUTLINE: This is a dose-escalation study. Patients are stratified according to age (under 50 vs 50

2001 Clinical Trials

3142. Vaccine Therapy in Treating Patients With Stage IV Head and Neck Cancer

: Absolute neutrophil count greater than 1,000/mm^3 Platelet count greater than 100,000/mm^3 Hemoglobin greater than 8 g/dL Hepatic: Bilirubin less than 1.5 mg/dL AST/ALT less than 4 times upper limit of normal (ULN) PT/PTT less than 1.5 times ULN Renal: Creatinine less than 2.0 mg/dL OR Creatinine clearance greater than 60 mL/min Cardiovascular: No evidence of congestive heart failure No serious cardiac dysrhythmia No evidence of recent prior myocardial infarction on EKG No clinical coronary artery (...) : Determine the maximum tolerated dose and dose-limiting toxic effects of recombinant fowlpox-TRICOM vaccine in patients with advanced squamous cell carcinoma of the oral cavity or oropharynx or nodal or dermal metastases. Determine the safety profile of this regimen in these patients. Determine the clinical activity of this regimen, in terms of inflammation at injection site(s) and disease regression or stabilization, in these patients. OUTLINE: This is a dose-escalation study. Patients receive

2001 Clinical Trials

3143. TLK286 in Treating Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

upper limit of normal Renal: Creatinine no greater than 1.5 mg/dL OR Creatinine clearance at least 60 mL/min No gross hematuria Cardiovascular: No uncontrolled cardiac arrhythmia No myocardial infarction within the past 6 months Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception during and for at least 6 months after study No unstable medical conditions No severe concurrent disease or infection that would preclude study No intestinal obstruction (...) cancer, fallopian tube cancer, or primary peritoneal cancer. Condition or disease Intervention/treatment Phase Fallopian Tube Cancer Ovarian Cancer Primary Peritoneal Cavity Cancer Drug: canfosfamide hydrochloride Phase 2 Detailed Description: OBJECTIVES: I. Determine the objective response rate and disease stabilization rate in patients with platinum-resistant advanced ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer treated with TLK286. II. Determine the safety

2001 Clinical Trials

3144. [Self-care in the prevention of sudden cardiac death]. (Abstract)

[Self-care in the prevention of sudden cardiac death]. In acute myocardial infarction a third up to half of death registered within the first month occur in the first hour of the onset of attack most frequently because of ventricular fibrillation. Immediate self administration of drugs stabilizing electrically the heart may prevent it. On the basis of experiments in dogs and in rats flunitrazepam (Rohypnol tabl. 1 mg), tramadol (Tramal caps. 50 mg) and the beta blocker metipranolol (Trimepranol (...) sleepy. There were no undesirable changes in the heart rate or blood pressure. In the three drug combination with metripranolol, the decrease in the heart rate was more marked. The tests in volunteers were without any undesirable effects and both combinations may, therefore, be given to selected high risk subjects, e g. convalescents from myocardial infarction. Randomized trial to prove the preventive effect already started.

1992 Vnitr̆ní lékar̆ství

3145. [A comparison of the clinical efficacy of enalapril maleate analogs in patients with heart failure and ischemic heart disease]. (Abstract)

[A comparison of the clinical efficacy of enalapril maleate analogs in patients with heart failure and ischemic heart disease]. The authors examined 68 patients aged from 42 to 68 years with ischemic heart disease without a history of myocardial infarction and with angina pectoris of exertion functional class 2-3 and circulatory insufficiency class 2 (according to NYHA criteria). The criteria serving as the reason for relating patients to the follow-up group were left-ventricular end-diastolic (...) volume > 160 ml, ejection fraction < 30%, cardiothoracic index > 0.55, threshold power of endured loads within a range of 71.5 +/- 2.30 watt. After stabilization of the clinical status by means of basic therapy (nitrates, blockers of slow calcium channels, diuretics, antiaggregants), all patients were divided into two follow-up groups. The first group consisted of 36 patients who received renitec (10 mg/24 h), patients of group 2 were given enap in the same dose. The course of treatment lasted 12

1998 Eksperimental'naia i klinicheskaia farmakologiia

3146. A comparison of the efficacy of sotalol and nadolol in the suppression of ventricular ectopic beats. (Abstract)

and no membrane-stabilizing action. Twenty-two patients with stable chronic ventricular arrhythmias after myocardial infarction were studied; to qualify for entry they had to exhibit a minimum frequency of 30 ventricular ectopic beats per hour over a 24-hour Holter monitoring period. The study was of single-blind, cross-over format with placebo periods before active drug administration and during the cross-over periods. Nadolol 80 and 160 mg and sotalol 160 and 320 mg were administered for 7-day periods

1983 South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde Controlled trial quality: uncertain

3147. Ibopamine as a substitute for digitalis in patients with congestive heart failure on chronic digoxin therapy. Smith Kline and French Ibopamine Group. (Abstract)

with ibopamine in any measured parameter. There were two deaths during the study: a sudden death and one following an acute myocardial infarction. Both patients were on digoxin. This study suggests that in patients with mild-to-moderate congestive heart failure, ibopamine therapy may effectively and safely substitute digoxin therapy for up to four weeks, representing an option for patients requiring inotropic support but are at risk for potential digoxin toxicity. (...) Ibopamine as a substitute for digitalis in patients with congestive heart failure on chronic digoxin therapy. Smith Kline and French Ibopamine Group. The substitution of digoxin with ibopamine, a new inotropic and vasodilating agent, was evaluated in a multicenter study in 58 patients with mild-to-moderate congestive heart failure, stabilized on diuretics, and digoxin therapy. The study was a parallel, double-blind, randomized trial of four weeks duration in which half of the group continued

1989 International journal of cardiology Controlled trial quality: uncertain

3148. Doxazosin for the treatment of chronic congestive heart failure: results of a randomized double-blind and placebo-controlled study. (Abstract)

of worsening heart failure severe enough to prompt discontinuation of the study, myocardial infarction, and death). Doxazosin was well tolerated, producing no major side effects and only a slightly higher frequency of minor treatment-related side effects compared with placebo (p = NS).(ABSTRACT TRUNCATED AT 250 WORDS) (...) Doxazosin for the treatment of chronic congestive heart failure: results of a randomized double-blind and placebo-controlled study. In this study we evaluated the effects of once-daily administration of oral doxazosin in patients with chronic congestive heart failure (CHF). After a stabilization period of at least 2 weeks with digitalis and diuretics, 73 patients with chronic CHF were randomized to receive additionally either doxazosin or placebo in double-blind fashion. Patients underwent

1991 American heart journal Controlled trial quality: uncertain

3149. Chemotherapy in Treating Women With Metastatic Breast Cancer

than 1.5 mg/dL SGOT or SGPT no greater than 2 times upper limit of normal (ULN) (5 times ULN if liver metastases present) Renal: Creatinine no greater than 2.0 mg/dL Cardiovascular: No active congestive heart failure No uncontrolled angina No myocardial infarction within past 6 months Neurologic: No history of an existing grade 3-4 peripheral neuropathy of any etiology Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception No allergy to camptothecin (...) therapy (e.g., patients with disease that is primarily resistant to hormonal therapy, patients without prior partial response, or stabilization of disease lasting less than 6 months) Patients with new or extensive visceral metastases Patients with rapidly progressive or symptomatic metastases during hormonal therapy Radiotherapy: See Disease Characteristics At least 4 weeks since prior radiotherapy and recovered No prior radiotherapy to greater than 50% of bone marrow No concurrent radiotherapy

2000 Clinical Trials

3150. SU5416 in Treating Patients With Advanced Solid Tumors

: No New York Heart Association class III or IV heart disease No uncompensated coronary artery disease on electrocardiogram or physical exam No myocardial infarction or severe or unstable angina within the past 6 months No severe peripheral vascular disease associated with diabetes mellitus No deep vein thrombosis or arterial thrombosis within the past 3 months Pulmonary: No pulmonary embolism within the past 3 months Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use (...) tumors. II. Determine the relationship between dose or plasma levels and the clinical safety profile and antitumor effects of this treatment regimen in terms of objective response, stabilization of disease, or progression-free survival in this patient population. III. Evaluate the relationship between dose or plasma levels of SU5416 concentrations and the ability of this treatment regimen to reduce microvessel density and induce apoptosis of endothelial and tumor cells in this patient population. IV

2000 Clinical Trials

3151. Mitomycin and Mitoxantrone in Treating Patients With Acute Myelogenous Leukemia

and SGPT no greater than 3 x normal Alkaline phosphatase no greater than 3 x normal No active hepatitis Renal: Not specified Cardiovascular: No myocardial infarction within last 6 months No congestive heart failure Ejection fraction greater than 50% (measured by MUGA or 2-D Echo) Pulmonary: No severe chronic obstructive pulmonary disease Other: No active infection or antimicrobiologically stabilized infection Not pregnant PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See

1999 Clinical Trials

3152. A Study on Possible Interactions Between Protease Inhibitors (Anti-HIV Drugs) and Drugs Which Lower the Level of Fat in Your Blood

the possibility of premature myocardial infarction has led health care providers and patients to consider treating these lipid metabolism disorders. Statin compounds have beneficial effects as lipid-lowering agents, and thereby reduce the risk of cardiovascular complications. Statin compounds such as pravastatin, simvastatin, and atorvastatin are increasingly being prescribed in persons taking PI-based potent antiretroviral therapy. It is important to determine whether there are significant drug-drug (...) interactions between the statin compounds and PIs. Fourteen healthy participants for each cohort of Arm A are stabilized on a fixed regimen of pravastatin (Arm A1), simvastatin (Arm A2), or atorvastatin (Arm A3) for 4 days. A baseline pharmacokinetic (PK) evaluation is completed on Day 4. Pravastatin (or simvastatin or atorvastatin) dosing stops following the Day 4 dose and PK evaluation. On Day 5, a ritonavir and saquinavir combination regimen is initiated and continued through Day 18 of the study

1999 Clinical Trials

3153. Paclitaxel in Advanced Refractory Kaposi's Sarcoma (AIDS-KS): A Phase II Trial of Paclitaxel From Baker Norton Pharmaceuticals

additional courses those who achieve partial response or stabilization, continue therapy until progression. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Primary Purpose: Treatment Official Title: Paclitaxel in Advanced Refractory Kaposi's Sarcoma (AIDS-KS): A Phase II Trial of Paclitaxel From Baker Norton Pharmaceuticals Resource links provided by the National Library of Medicine related topics: available for: resources: Arms and Interventions Go (...) . Failed at least one systemic chemotherapy regimen. Exclusion Criteria Co-existing Condition: Patients with the following conditions and symptoms are excluded: Less than 2 weeks since major surgery. Serious uncontrolled infection. NOTE: Must be ruled out by thorough work-up in patients with unexplained fevers, night sweats, or involuntary weight loss of more than 10% normal weight. Leukopenia. Thrombocytopenia. Patients with the following prior conditions are excluded: History of angina or myocardial

1999 Clinical Trials

3154. A Study of WF 10 IV Solution in Patients With Advanced HIV Disease

: Neoplasm other than basal cell carcinoma of the skin. Clinically significant cardiac disease. Anemia. Concurrent Medication: Excluded: Cytotoxic chemotherapy. Corticosteroids. Patients with the following prior conditions are excluded: History of myocardial infarction or arrhythmias. Prior Medication: Excluded within 2 weeks prior to study entry: Any antiretroviral agent. Interferon. Systemic therapy with biologic response modifiers, corticosteroids, cytotoxic chemotherapy, or neutropenic or nephrotoxic (...) Concurrent Medication: Allowed: Approved drugs at a stabilized dose except those specifically excluded. Aerosolized pentamidine (300 mg) once a month for PCP prophylaxis. Patients must have: HIV positivity. Absolute CD4 count < 200 cells/mm3. Intolerance to or refusal to take AZT, ddI, ddC, or d4T. No active opportunistic infection requiring ongoing therapy. Life expectancy at least 3 months. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded

1999 Clinical Trials

3155. Lung Health Study II

) < 70 percent Forced expiratory volume at one second (FEV1) 30 to 90 percent predicted. Exclusions: Cancer Recent myocardial infarction Alcoholism Heart Failure Insulin-dependent diabetes mellitus Neuropsychiatric disorders Used bronchodilators or oral or inhaled corticosteroids in previous year Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided (...) in the development of emphysema. On this basis, the rationale for the use of corticosteroids is well justified. There are various published studies suggesting that inhaled steroids reduce bronchial lavage markers of inflammation, variously influence short-term bronchial hyperreactivity, improve lung function acutely or short-term, and slow rate of decline in lung function. Most studies have asked for improvement rather than stability. However, despite the studies which do not support these contentions

1999 Clinical Trials

3156. Shock Trial: Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock.

ventricular failure complicating myocardial infarction were randomly assigned to emergency revascularization or initial medical stabilization. Revascularization was accomplished by either coronary-artery bypass grafting or angioplasty. A total of 152 patients were randomized to early revascularization and 150 patients to conventional therapy consisting of thrombolytics and a possible late attempt at revascularization. Intraaortic balloon counterpulsation was performed in 86 percent of the patients in both (...) Myocardial Infarction Myocardial Ischemia Shock, Cardiogenic Procedure: angioplasty, transluminal, percutaneous coronary Procedure: coronary artery bypass Drug: thrombolytic therapy Phase 3 Detailed Description: BACKGROUND: Approximately 7.5 percent of all acute myocardial infarctions which are diagnosed in an emergency room or in-hospital lead to cardiogenic shock and an in-hospital death rate of 70 to 80 percent, usually within one to two days of diagnosis of cardiogenic shock. The high death rate has

1999 Clinical Trials

3157. Combination Chemotherapy With or Without PSC 833 in Treating Patients With Relapsed or Refractory Multiple Myeloma

at least 1,000/mm^3 Platelet count at least 50,000/mm^3 Hepatic: Bilirubin less than 1.5 times upper limit of normal (ULN) AST less than 1.5 times ULN No chronic or active hepatitis or cirrhosis Renal: Creatinine less than 3.0 mg/dL Cardiovascular: Ejection fraction at least 50% No history of congestive heart failure No overt angina despite medication No myocardial infarction within 2 months No poorly controlled hypertension (i.e., pressure 200/110 or higher despite medication) No arrhythmia requiring (...) No uncontrolled diabetes mellitus No second malignancy within the past 5 years except curatively treated nonmelanomatous skin cancer, carcinoma in situ of the cervix, or other localized cancer treated with surgery alone Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception No other serious medical problem unless sufficiently stabilized PRIOR CONCURRENT THERAPY: Biologic therapy: Prior biologic therapy (e.g., interferon) allowed Chemotherapy: See Disease

1999 Clinical Trials

3158. Effects of perioperative dexmedetomidine infusion in patients undergoing vascular surgery. The Study of Perioperative Ischemia Research Group. (Abstract)

. Postoperatively, demedetomidine groups had less tachycardia (minutes/monitored hours) than the placebo group (placebo 23 min/h; low dose 9 min/h, P = 0.006; medium dose 0.5 min/h, P = 0.004; high dose 2.3 min/h, P = 0.004). Bradycardia was rare in all groups. There were no myocardial infarctions or discernible trends in the laboratory results.Infusion of dexmedetomidine up to a targeted plasma concentration of 0.45 ng/ml appears to benefit perioperative hemodynamic management of surgical patients undergoing (...) Effects of perioperative dexmedetomidine infusion in patients undergoing vascular surgery. The Study of Perioperative Ischemia Research Group. Dexmedetomidine, a highly selective alpha 2-adrenergic agonist, increases perioperative hemodynamic stability in healthy patients but decreases blood pressure and heart rate. The goal of this study was to evaluate, in a preliminary manner, the hemodynamic effects of perioperatively administered dexmedetomidine in surgical patients at high risk

1995 Anesthesiology Controlled trial quality: uncertain

3159. Effectiveness of prolonged low dose recombinant tissue-type plasminogen activator for refractory unstable angina. Full Text available with Trip Pro

% vs. 12.9%, p < 0.01) developed acute myocardial infarction during the hospital period. Eight patients in group B underwent emergency coronary artery surgery or angioplasty because of worsening of symptoms. Group A patients had a significant reduction in the occurrence of chest pain compared with those in group B (95% confidence interval -7.2 to -2.1 episodes/3 days, p < 0.01). Patients in group B had a greater number of episodes of transient myocardial ischemia (237 vs. 103, p < 0.01 (...) ) and a longer total ischemic burden (114 +/- 23 vs. 45.6 +/- 8.9 min/day, p < 0.01) than group A patients. After a mean follow-up of 14 +/- 6 months, group A patients were more frequently angina free and had a lower incidence of readmission to the hospital than group B patients.The combination of heparin and protracted administration of rt-PA at low doses is effective in stabilizing and reducing in-hospital adverse events in patients with unstable angina refractory to antianginal therapy.

1995 Journal of the American College of Cardiology Controlled trial quality: uncertain

3160. Continuous infusions of alfentanil and propofol for coronary artery surgery. (Abstract)

) and in the number of alfentanil bolus supplements. There were also no differences in the incidence of ischemia, myocardial infarction or duration of postoperative ventilation.Because both infusions provided equally stable anesthesia, the lower infusion regimen for alfentanil is the more appropriate technique. Using this technique, the administration of additional alfentanil boluses just before stressful surgical episodes will further improve hemodynamic stability. (...) Continuous infusions of alfentanil and propofol for coronary artery surgery. To study the anesthetic efficacy of two different background infusion rates for alfentanil in a total intravenous anesthesia (TIVA) technique using propofol. Therefore, the effects of these infusions on hemodynamic stability and on the suppression of hemodynamic and somatic responses to noxious stimuli were compared.Prospective and randomized.The study was performed in a university hospital setting. Two patient groups

1995 Journal of cardiothoracic and vascular anesthesia Controlled trial quality: uncertain

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>